Lumexa Imaging (LMRI) reports director award of 27,027 RSUs

Rhea-AI Filing Summary

Lumexa Imaging Holdings, Inc. reported that a company director acquired 27,027 shares of common stock on 12/12/2025 through a restricted stock unit grant at a price of $0 per share. Following this grant, the director beneficially owns 27,027 shares held directly.

The award consists of restricted stock units, each representing the contingent right to receive one share of common stock. Of these units, 13,513 vested on the grant date, and the remaining units are scheduled to vest in three substantially equal annual installments on each of the first three anniversaries of the grant date, subject to the director’s continued service with the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Joseph Molly

(Last) (First) (Middle)

4200 SIX FORKS ROAD

SUITE 1000

(Street)

RALEIGH NC 27609

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lumexa Imaging Holdings, Inc. [ LMRI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		A		27,027(1)	A	$0	27,027	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSUs"), each one of which represents the contingent right to receive one share of the Issuer's common stock. 13,513 RSUs vested on the grant date, and the remaining RSUs will vest annually in three substantially equal installments on each of the first three anniversaries of the grant date, subject to the Reporting Person's continued service with the Issuer.

	/s/ Julie Szeker, attorney-in-fact	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Lumexa Imaging Holdings (LMRI) disclose?

Lumexa Imaging Holdings disclosed that a company director acquired 27,027 shares of its common stock on 12/12/2025 through a restricted stock unit (RSU) grant at a price of $0 per share.

How many shares does the Lumexa Imaging (LMRI) director own after this grant?

After the reported RSU grant, the director beneficially owns 27,027 shares of Lumexa Imaging Holdings common stock held directly.

What are the vesting terms of the RSUs reported by Lumexa Imaging (LMRI)?

The RSU award covers 27,027 units. Of these, 13,513 RSUs vested on the grant date, and the remaining RSUs will vest in three substantially equal annual installments on each of the first three anniversaries of the grant date, subject to the director’s continued service.

What does each RSU in the Lumexa Imaging (LMRI) grant represent?

Each restricted stock unit in the grant represents the contingent right to receive one share of Lumexa Imaging Holdings, Inc. common stock.

What is the relationship of the reporting person to Lumexa Imaging (LMRI)?

The reporting person for this transaction is identified as a director of Lumexa Imaging Holdings, Inc.

Was any cash paid for the Lumexa Imaging (LMRI) RSU grant?

No cash was paid for the shares underlying this RSU grant, as the common stock was reported as acquired at a price of $0 per share.